Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma

21 Mar 2022

Abstract excerpt

BACKGROUND: MDM2 is elevated in multiple myeloma (MM). Although traditionally, MDM2 negatively regulates p53, a growing body of research suggests that MDM2 plays several p53-independent roles in cancer pathogenesis as a regulator of oncogene mRNA stability and translation. Yet, the molecular mechanisms underlying MDM2 overexpression and its role in drug resistance in MM remain undefined. METHODS: Both myeloma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35326742
DOI: 10.3390/cancers14061592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple MyelomaPMID 35326742Read ↗

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.Semantic proximity Read ↗

Deregulation and Targeting of TP53 Pathway in Multiple MyelomaSemantic proximity Read ↗

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanismsSemantic proximity Read ↗

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.Semantic proximity Read ↗

Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma.Semantic proximity Read ↗

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsSemantic proximity Read ↗

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic ResponsesSemantic proximity Read ↗

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read ↗

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple MyelomaSemantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

Role of micro-RNAs in drug resistance of multiple myelomaSemantic proximity Read ↗

Targeting the miR-221–222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.